Go Pro
LON:GENI

GENinCode Interim Earnings Report

GENinCode logo
GBX 0.76 -0.04 (-5.50%)
As of 07:03 AM Eastern

GENinCode EPS Results

Actual EPS
-GBX 1.19
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

GENinCode Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

GENinCode Announcement Details

Quarter
Interim
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

GENinCode Earnings Headlines

AIM Market Roundup: Marechale Capital, Genincode, Boohoo
ALERT: Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings research points to the first half of 2026 as a particularly rough stretch for certain holdings. Some of America's most popular stocks could take serious damage as a radical market shift plays out. Analysts at Weiss Ratings have identified five names you may want to remove from your portfolio before this unfolds. If any of these are in your portfolio, now is the time to review your positions.tc pixel
GENinCode slumps after it reprices options
AIM Market Roundup: Phoenix Copper, Pipehawk, Genincode
See More GENinCode Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like GENinCode? Sign up for Earnings360's daily newsletter to receive timely earnings updates on GENinCode and other key companies, straight to your email.

About GENinCode

GENinCode (LON:GENI) is a UK based company specialising in genetic risk assessment of cardiovascular disease. Cardiovascular disease is the leading cause of death and disability worldwide. GENinCode operates business units in the UK, in the United States through GENinCode U.S. Inc and in Europe through GENinCode S.L.U. GENinCode predictive technology provides patients and physicians with globally leading preventative care and treatment strategies. GENinCode CE marked invitro-diagnostic molecular tests combine clinical algorithms and bioinformatics to provide advanced patient risk assessment to predict disease onset.

View GENinCode Profile